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The dynamic crosstalk between cancer cells 
and tumor stroma is a major determinant of disease 
aggressiveness. Factors released by cancer cells (proteins, 
growth factors, cytokines, small RNAs) induce a stromal 
response involving fibroblast activation, intra-tumoral 
angiogenesis, and leukocyte infiltration; in turn, activated 
stromal cells remodel the extracellular matrix and release 
signals that can modify the behavior of cancer cells, e.g. 
promoting a mesenchymal-like phenotype [1, 2]. This 
reciprocal cell-to-cell communication profoundly affects 
tumor vascularization via crosstalk with endothelial 
cells [3], with implications for cancer growth and 
dissemination. In this context, signaling modulators 
that control specificity, amplitude, and duration of cell 
responses to external inputs can play a crucial role - often 
underestimated.
One such modulator is the tumor suppressor 
DAB2IP (Disabled 2 interacting protein), also known 
as AIP1 (Ask1 interacting protein). DAB2IP is a 
cytoplasmic Ras inhibitor (Ras-GAP) that also restrains 
NF-kB activation by inflammatory cytokines, and 
PI3K-AKT activation by various growth factors. More 
generally, DAB2IP acts as a cytoplasmic adaptor in 
signal transduction, negatively regulating multiple 
oncogenic pathways both in epithelial and in endothelial 
cells. Substantial evidence indicates that DAB2IP loss of 
function promotes epithelial to mesenchymal transition 
(EMT) and enhances invasiveness, proliferation, stemness, 
and chemoresistance in various cancer cell models [4, 5]. 
Accordingly, several mechanisms of DAB2IP inactivation 
have been described, ranging from promoter methylation 
to inhibitory interaction with mutant p53, to post-
transcriptional downregulation by miRNAs [4, 5].
Performing a high-throughput functional screening, 
we identified a panel of microRNAs able to target the 
mRNA of DAB2IP. Among them, we characterized 
miRNA-149-3p as a potent antagonist of DAB2IP protein 
synthesis and DAB2IP oncosuppressive functions [6]. 
We observed that miR-149-3p expression in prostate 
cancer cell lines counteracts DAB2IP action, favoring an 
immunogenic and pro-angiogenic NF-kB-related gene 
expression program, and an invasive phenotype. We have 
successfully used LNAs (Locked Nucleic Acids) to mask 
the miR-149-3p seed sequences on DAB2IP mRNA, 
demonstrating that inhibition of miR-149-3p in malignant 
cells stabilizes DAB2IP protein levels and functions, and 
formally proving that the observed pro-oncogenic effects 
of miR-149-3p are mediated by its action on DAB2IP. In 
vivo xenograft experiments supported the in vitro results: 
inhibition of miR-149-3p counteracted prostate cancer 
cell dissemination in nude mice, and reduced cancer cell 
growth and angiogenic remodeling in zebrafish larvae [6].
Intriguingly, our functional screening identified 
both strands of miR-149 as positive hits: despite having 
different seed sequences, both miR-149-3p and miR-
149-5p can target the DAB2IP mRNA. However, the 
consequences of their overexpression in tumor cells 
are different, since only miR-149-3p has a pro-invasive 
effect. We think this is due to the action of miR-149-5p 
on additional oncogenic cellular targets, counteracting 
tumor cell invasiveness [7]. Thus, cell behavior can be 
deeply affected by the relative concentrations of the two 
miR-149 strands. The expression of individual miRNA 
strands depends on molecular parameters controlling 
pri- and pre-miRNA processing, as well as co-factors 
modulating miRNA activity and stability; deregulation 
of such controls in human malignancies could contribute 
to the acquisition of oncogenic features by selectively 
potentiating miR-149-3p levels and functions.
In addition to inducing cell-autonomous effects, 
expression of miR-149-3p in cancer cells can possibly 
act also on the tumor microenvironment. Starting from 
evidence that miR-149-3p is secreted by cancer cells and 
can be detected in the plasma of melanoma patients [6, 
7], we proved that secreted miR-149-3p induces DAB2IP 
downregulation in non-transformed cell lines and in 
primary endothelial cells, affecting their behavior and 
their response to secreted growth factors and cytokines. 
DAB2IP is abundantly expressed in endothelial cells, 
where its depletion increases proliferation, migration, 
tube formation capabilities, and vascular permeability [6, 
8]. A recent study demonstrated that conditional DAB2IP 
knockout in vascular endothelial cells facilitates formation 
of a pre-metastatic niche, increasing tumor growth and 
dissemination in mouse models of melanoma and breast 
cancer [8]. These results imply that DAB2IP may have a 
relevant tumor-suppressive role in controlling the behavior 
of stromal cells; at the same time, they raise the question 
of whether DAB2IP is actually inactivated in tumor-
associated vascular endothelial cells - and how.
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We observed DAB2IP downregulation in endothelial 
cells treated with medium conditioned by prostate cancer 
cells. This is a possible mechanism by which cancer cells 
can inactivate DAB2IP in stromal cells, to establish a 
supporting microenvironment that could facilitate tumor 
growth and dissemination - exactly as modeled in mice 
by conditional knockout [6]. We found that miR-149-3p 
partially mediates this phenotype in prostate cancer cell 
lines, but additional factors are likely to be involved, 
including other DAB2IP-targeting miRNAs. Perhaps a 
variable cocktail of secreted miRNAs could modulate 
DAB2IP expression and functions in stromal cells of 
different tumor types. Also, the action of secreted miRNAs 
could integrate and complement the action of growth-
factors and cytokines in the tumor microenvironment.
Further studies will be required to define 
mechanisms and impact of cell non-autonomous DAB2IP 
inhibition in endothelial cells, and possibly in other 
stromal cells. Results of these studies may provide 
additional insights on the reciprocal regulation between 
tumor and stroma in cancer progression, and may reveal 
novel targets for therapy.
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